BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2021 8:21:53 AM | Browse: 688 | Download: 1542
 |
Received |
|
2021-03-11 03:27 |
|
Peer-Review Started |
|
2021-03-11 03:31 |
|
First Decision by Editorial Office Director |
|
2021-05-11 20:46 |
|
Return for Revision |
|
2021-05-11 20:46 |
|
Revised |
|
2021-05-20 01:29 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-12 03:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-12 06:00 |
|
Articles in Press |
|
2021-07-12 06:00 |
|
Edit the Manuscript by Language Editor |
|
2021-11-28 13:52 |
|
Typeset the Manuscript |
|
2021-12-26 15:00 |
|
Publish the Manuscript Online |
|
2021-12-30 08:21 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Successful response to camrelizumab in metastatic bladder cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chen Xie, Xia Yuan, Shu-Hui Chen, Zhi-Yong Liu, Di-La Lu, Feng Xu, Zhi-Qiu Chen and Xiao-Ming Zhong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiao-Ming Zhong, PhD, Chief Doctor, Department of Radiology, Jiangxi Provincial Tumour Hospital, No. 519 Beijing East Road, Nanchang 330029, Jiangxi Province, China. jddxf2012@126.com |
| Key Words |
Programmed death-ligand 1; Tumor mutational burden; Bladder cancer; Camrelizumab; Next-generation sequencing; Case report |
| Core Tip |
Eighty percent of patients with positive programmed death-ligand 1 (PD-L1) are unable to benefit from immunotherapy. Herein, we report a case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high tumor mutational burden. Immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with progression-free survival of 11 mo. More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor. |
| Publish Date |
2021-12-30 08:21 |
| Citation |
Xie C, Yuan X, Chen SH, Liu ZY, Lu DL, Xu F, Chen ZQ, Zhong XM. Successful response to camrelizumab in metastatic bladder cancer: A case report. World J Clin Cases 2022; 10(1): 254-259
|
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i1/254.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i1.254 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
